Abstract
Interleukin-18 (IL-18) plays a role in the host's response to tumours and angiogenesis. We determined serum levels of IL-18, vascular endothelial growth factor (VEGF), angiogenin (ANG), tumor necrosis factor (TNF-alpha) and CRP in 65 newly diagnosed myeloma patients. IL-18, VEGF, angiogenin, TNF-alpha and CRP were significantly higher at stage III in comparison to stages II and I. These cytokines (measured in 27 patients) significantly decreased after treatment. In survival analysis, higher levels of IL-18 were associated with a poorer prognosis. We conclude that increased serum IL-18 in myeloma patients correlates with advanced disease, increased levels of angiogenic cytokines and worse survival.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
C-Reactive Protein / analysis
-
Dexamethasone / administration & dosage
-
Disease Progression
-
Doxorubicin / administration & dosage
-
Female
-
Humans
-
Interleukin-18 / blood*
-
Life Tables
-
Male
-
Melphalan / administration & dosage
-
Middle Aged
-
Multiple Myeloma / blood*
-
Multiple Myeloma / drug therapy
-
Multiple Myeloma / mortality
-
Neoplasm Proteins / blood*
-
Prednisone / administration & dosage
-
Prospective Studies
-
Ribonuclease, Pancreatic / blood
-
Survival Analysis
-
Tumor Necrosis Factor-alpha / analysis
-
Vascular Endothelial Growth Factor A / blood
-
Vincristine / administration & dosage
Substances
-
Interleukin-18
-
Neoplasm Proteins
-
Tumor Necrosis Factor-alpha
-
Vascular Endothelial Growth Factor A
-
Vincristine
-
Dexamethasone
-
Doxorubicin
-
C-Reactive Protein
-
angiogenin
-
Ribonuclease, Pancreatic
-
Melphalan
-
Prednisone
Supplementary concepts
-
AP protocol 2
-
VAD protocol